NCT03834740View on ClinicalTrials.gov

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 19, 2019

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions
Glioblastoma MultiformeGlioma of Brain
Interventions
DRUG

Ribociclib

Ribociclib administered orally in 5 daily doses prior to resection

DRUG

Everolimus

Everolimus administered orally in 5 daily doses prior to resection

Trial Locations (3)

85013

St. Joseph's Hospital and Medical Center, Phoenix

85224

Chandler Regional Medical Center, Chandler

85251

HonorHealth Scottsdale Osborn Medical Center, Scottsdale

All Listed Sponsors
collaborator

Ivy Brain Tumor Center

OTHER

collaborator

Barrow Neurological Institute

OTHER

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT03834740 - A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | Biotech Hunter | Biotech Hunter